# Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

> **NCT02230995** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** metformin
- **DRUG:** empagliflozin/metformin
- **DRUG:** empagliflozin

## Key facts

- **NCT ID:** NCT02230995
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230995, "Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02230995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*